Further, the persistent formation of the eIF4F complex, comprising the eIF4E cap-binding protein, the eIF4G scaffolding protein, and the eIF4A RNA helicase, was associated with resistance to BRAFi, MEKi, and BRAFi/MEKi combination in BRAFV600E melanoma, colon, and thyroid cancer cells. The gene discussed is EIF4E; the disease is thyroid gland carcinoma.